XinThera, LLC
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
XinThera, LLC - overview
Established
2021
Location
San Diego, CA, US
Primary Industry
Biotechnology
About
Based in San Diego, US, and founded in 2021, XinThera, LLC. provides precision medicines to treat cancer and immunological diseases. In August 2021, the firm raised USD 50 million in Series B funding from investor OrbiMed Advisors. As of 2022, the company was headed by its CEO Chris LeMasters.
The company offers new opportunities and new therapies that can be used to treat cancer and immunological diseases. The firm designs medicines for the patient by using advanced computational chemistry technologies. The company plans to use the August 2022 funding to support its recruiting efforts and build its product pipeline.
Current Investors
OrbiMed Advisors, Foresite Capital, TTM Capital
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy
Total Amount Raised
Subscriber access only
XinThera, LLC - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.